<unk> , sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed or relapsed/refractory multiple myeloma. It is a combination of<unk>  and hyaluronidase. It is administered via subcutaneous injection. The most common adverse reaction using<unk>  as monotherapy is upper respiratory tracts infection. The most common adverse reactions (≥20%) in people with amyloid light-chain amyloidosis who received<unk>  in combination with bortezomib, cyclophosphamide, and dexamethasone are upper respiratory tract infection, diarrhea, peripheral edema, constipation peripheral sensory neuropathy, fatigue, nausea, insomnia, dyspnea and cough. The most common adverse reactions (≥20%) occurring in people treated with<unk> , carfilzomib, and dexamethasone were upper respiratory tract infections, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea, and edema peripheral.
Daratumumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Enfortumab vedotin
Peginterferon beta-1a
Peginterferon alfa-2a
Interferon beta-1a
Interferon beta-1b
Peginterferon alfa-2b